Literature DB >> 8011800

Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects.

H Y Meltzer1, M Maes.   

Abstract

The cortisol response to ipsapirone (a 5-HT1A-partial agonist that produces a dose-dependent increase in plasma cortisol secretion in man) is blunted in major depression. Buspirone is another 5-HT1A agonist that increases cortisol secretion in man. This study investigated cortisol and prolactin (PRL) responses to buspirone (30 mg orally) in 45 major depressed subjects and 28 normal controls. Buspirone administration yielded a significant increase in cortisol and PRL levels in both normal controls and depressed subjects. No differences in buspirone-induced hormone responses were found either between major depressives and normal controls or between melancholic and nonmelancholic depressives. There were no significant relationships between severity of depression and any of the hormonal responses to buspirone. PRL responses to buspirone were significantly higher in women than in men.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8011800     DOI: 10.1016/0006-3223(94)90035-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  4 in total

Review 1.  5-HT(1A) receptor function in major depressive disorder.

Authors:  Jonathan Savitz; Irwin Lucki; Wayne C Drevets
Journal:  Prog Neurobiol       Date:  2009-02-07       Impact factor: 11.685

Review 2.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

3.  Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.

Authors:  Kari Laine; Outi Ahokoski; Risto Huupponen; Jutta Hänninen; Sanna Palovaara; Jori Ruuskanen; Harry Björklund; Markku Anttila; Juha Rouru
Journal:  Eur J Clin Pharmacol       Date:  2003-10-18       Impact factor: 2.953

4.  Pharmacological causes of hyperprolactinemia.

Authors:  Daria La Torre; Alberto Falorni
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.